These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7788012)

  • 1. Growth hormone response to growth hormone-releasing hormone (GHRH), insulin, clonidine and arginine after GHRH pretreatment in obese children: evidence of somatostatin increase?
    Volta C; Bernasconi S; Iughetti L; Ghizzoni L; Rossi M; Costa M; Cozzini A
    Eur J Endocrinol; 1995 Jun; 132(6):716-21. PubMed ID: 7788012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GH response to GHRH, insulin, clonidine and arginine after GHRH pretreatment in children.
    Bernasconi S; Volta C; Cozzini A; Ziveri M; Ghizzoni L; Panza C; Ghigo E
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):105-8. PubMed ID: 1543013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M; Maccario M; Grottoli S; Oleandri SE; Boffano GM; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
    Loche S; Pintor C; Cappa M; Ghigo E; Puggioni R; Locatelli V; Müller EE
    Acta Endocrinol (Copenh); 1989 May; 120(5):624-8. PubMed ID: 2499149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha 2-adrenergic agonism enhances the growth hormone (GH) response to GH-releasing hormone through an inhibition of hypothalamic somatostatin release in normal men.
    Devesa J; Arce V; Lois N; Tresguerres JA; Lima L
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1581-8. PubMed ID: 1977761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.
    Ghigo E; Procopio M; Boffano GM; Arvat E; Valente F; Maccario M; Mazza E; Camanni F
    Metabolism; 1992 May; 41(5):560-3. PubMed ID: 1588839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone release during insulin tolerance, clonidine, arginine and growth hormone releasing hormone tests in short normal children and adolescents.
    Cavallo L; Acquafredda A; Liuzzi S; Russo R; Zecchino C; Leuzzi R; Giobbe T; Piacente L
    J Endocrinol Invest; 1992 Feb; 15(2):131-5. PubMed ID: 1569289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.
    Ghigo E; Mazza E; Corrias A; Imperiale E; Goffi S; Arvat E; Bellone J; De Sanctis C; Müller EE; Camanni F
    Metabolism; 1989 Jul; 38(7):631-3. PubMed ID: 2500577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH release in normal subjects.
    Hanew K; Utsumi A
    Eur J Endocrinol; 2002 Feb; 146(2):197-202. PubMed ID: 11834428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of atenolol on the growth hormone response to growth hormone-releasing hormone in obese children.
    Loche S; Pintus S; Carta D; Muntoni AC; Congiu G; Civolani P; Pintor C
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):124-7. PubMed ID: 1311892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.
    Ghigo E; Bellone J; Aimaretti G; Bellone S; Loche S; Cappa M; Bartolotta E; Dammacco F; Camanni F
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3323-7. PubMed ID: 8784091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.